# STANDARD BIOTOOLS INC. (LAB) — merger/definitive [completed] Source: SEC API (secapi.ai) · situation sit_fdcac12d0e0689959794 · retrieved 2026-08-11T16:15:05.809Z ## Overview Standard BioTools Inc. develops and sells mass cytometry-based products and technologies, including the CyTOF platform, Hyperion spatial biology platform, Maxpar reagents, and Theia next-generation XTi platform, along with associated panels, assays, and antibodies. Standard BioTools Inc. agreed to sell its mass cytometry business, including the CyTOF platform, Hyperion spatial biology platform, Maxpar reagents, and Theia next-generation XTi platform, to Multiplex Bio Inc. pursuant to a Share and Asset Purchase Agreement dated July 28, 2026. The transaction includes a base purchase price of $5,000,000 plus assumption of certain liabilities and working capital adjustments, with an additional $5,000,000 in contingent consideration payable upon a Qualifying Exit (defined as a sale, merger, IPO, or change of control of Buyer with aggregate transaction value exceeding a specified threshold) within ten years of closing. The sale is subject to stockholder approval and customary closing conditions. ## Terms - Counterparty: Multiplex Bio Inc. · Deal value: $5.0M · Consideration: cash ## Key dates - Announced 2026-07-28 · Expected close 2026-12-31 · Completed 2026-07-20 ## Timeline - 2026-07-20 · 425 (0001140361-26-028877): 425 - STANDARD BIOTOOLS INC. — *Standard BioTools Inc. is a life science tools company committed to setting the new standard in the industry through strategic consolidation and best-in-class operations, with an established portfolio of essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster.* Standard BioTools Inc. announced the filing of a Form S-4 registration statement in connection with its previously announced definitive merger agreement with Treeline Biosciences, Inc. The all-stock merger is expected to close in the second half of 2026, with the combined company operating under the name Treeline Biosciences Holdings, Inc. and trading on Nasdaq under ticker symbol "TRLN". At closing, the combined company is expected to have more than $900 million in pro-forma cash, which is expected to fund operations and support Treeline's development pipeline into 2029. https://www.sec.gov/Archives/edgar/data/1162194/0001140361-26-028877.txt - 2026-07-28 · 425 (0001140361-26-029842): 425 - STANDARD BIOTOOLS INC. — *Standard BioTools Inc. develops and commercializes life science tools including mass cytometry instruments (CyTOF and Hyperion) for biomedical research, and is pursuing a merger with Treeline Biosciences.* Standard BioTools Inc. entered into a Share and Asset Purchase Agreement with Multiplex Bio Inc. on July 28, 2026, to sell its mass cytometry business (CyTOF and Hyperion product lines). The aggregate purchase price is $5 million on a cash-free, debt-free basis, payable entirely through a promissory note bearing 6% interest and maturing five years from closing. Standard BioTools may receive an additional $5 million if Multiplex Bio consummates a qualifying sale transaction exceeding a specified threshold within ten years. The transaction requires Standard BioTools stockholder approval and is expected to close by end of 2026, substantially concurrently with Standard BioTools' pending merger with Treeline Biosciences. https://www.sec.gov/Archives/edgar/data/1162194/0001140361-26-029842.txt - 2026-07-28 · 425 (0001140361-26-029844): 425 - STANDARD BIOTOOLS INC. — *Standard BioTools Inc. (formerly Fluidigm Corp) is a life sciences company that develops and commercializes mass cytometry and multiplex imaging platforms including CyTOF and Hyperion systems for research and clinical applications.* Standard BioTools announced the sale of its Mass Cytometry business (CyTOF, Hyperion, and next-generation multiplex product lines) to Multiplex Bio, a private company led by advanced imaging industry veterans. The transaction is expected to close by the end of 2026, substantially concurrently with Standard BioTools' separate Treeline transaction. Post-closing, the business will maintain full continuity including customer relationships, the majority of the team, and existing service and maintenance commitments. The company has explored multiple opportunities and determined Multiplex Bio is the best home for the technology and team. https://www.sec.gov/Archives/edgar/data/1162194/0001140361-26-029844.txt - 2026-07-29 · 425 (0001140361-26-029965): 425 - STANDARD BIOTOOLS INC. — *Standard BioTools Inc. develops and sells mass cytometry-based products and technologies, including the CyTOF platform, Hyperion spatial biology platform, Maxpar reagents, and Theia next-generation XTi platform, along with associated panels, assays, and antibodies.* Standard BioTools Inc. agreed to sell its mass cytometry business, including the CyTOF platform, Hyperion spatial biology platform, Maxpar reagents, and Theia next-generation XTi platform, to Multiplex Bio Inc. pursuant to a Share and Asset Purchase Agreement dated July 28, 2026. The transaction includes a base purchase price of $5,000,000 plus assumption of certain liabilities and working capital adjustments, with an additional $5,000,000 in contingent consideration payable upon a Qualifying Exit (defined as a sale, merger, IPO, or change of control of Buyer with aggregate transaction value exceeding a specified threshold) within ten years of closing. The sale is subject to stockholder approval and customary closing conditions. https://www.sec.gov/Archives/edgar/data/1162194/0001140361-26-029965.txt ## Citations - 0001140361-26-028877 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000114036126028877 - 0001140361-26-029842 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000114036126029842 - 0001140361-26-029844 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000114036126029844 - 0001140361-26-029965 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000114036126029965